Quintrio
Home

SERVICES-MISC HEALTH & ALLIED SERVICES, NEC

Cryo-Cell International Inc.

CCEL

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

Last trade $4.67
Day change +$0.1204 (+2.65%)
Day range $4.28 – $4.75
Volume 16,886
Market cap $37M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$36.69M
Price / earnings
—
Price / book
-2.24×
Price / sales
1.18×
EV / sales
1.43×
EV / EBITDA
8.05×

Profitability

Earnings per share
-$0.24
Return on assets
-3.12%
Return on equity
11.87%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.56×
Current ratio
0.86×
Quick ratio
0.82×
Cash ratio
0.09×

Cash flow

Price / cash flow
7.46×
Price / free cash flow
7.89×
Free cash flow
$4.65M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CCEL, quarterly periods
Line itemQ3 FY2026 Aug 31, 2026Q2 FY2026 May 31, 2026Q1 FY2026 Feb 28, 2026Q4 FY2025 Nov 30, 2025Q3 FY2025 Aug 31, 2025Q2 FY2025 May 31, 2025Q1 FY2025 Feb 28, 2025Q4 FY2024 Nov 30, 2024
Revenue$7.82M$7.78M$7.68M$7.84M$7.83M$7.93M$7.97M$8.02M
Cost of revenue$1.61M$1.68M$1.66M$1.73M$1.8M$1.86M$1.98M$1.64M
Gross profit$6.21M$6.1M$6.03M$6.11M$6.02M$6.07M$5.98M$6.39M
Selling, general and administrative$3.78M$4.62M$5.01M$5.45M$3.88M$4.26M$4.64M$6.01M
Research and development$53.62K$99.78K$65.76K$84.78K$61.63K$131.71K$98.14K$304.63K
Total operating expenses$4.02M$4.9M$5.26M$10.08M$4.12M$4.58M$4.93M$6.2M
Operating income$2.19M$1.2M$765.13K-$3.97M$1.9M$1.49M$1.06M$185.65K
Interest expense-$438.31K-$441.92K-$462.71K-$481.95K-$538.22K-$551.13K-$494.96K-$745.49K
Income before taxes$1.83M$827.78K$70.31K-$4.63M$1.19M$575.1K$533.72K-$842.43K
Income taxes$554.96K$273.2K$23.2K-$814.54K$436.59K$219.32K$250.86K$1.02M
Net income$1.27M$554.59K$47.11K-$3.82M$749.41K$355.79K$282.86K-$1.86M
Net income attributable to common shareholders$1.27M$554.59K$47.11K-$3.82M$749.41K$355.79K$282.86K-$1.86M
EBITDA$2.43M$1.44M$1.01M$635.06K$2.14M$1.74M$1.3M$434.65K
Basic earnings per share$0.16$0.07$0.01-$0.47$0.09$0.04$0.03-$0.23
Diluted earnings per share$0.16$0.07$0.01-$0.48$0.09$0.04$0.03-$0.23

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Cord Blood Banking Services Market: USD 49.85 Bn Opportunity to 2031 Led by Stem Cell Advancements, Says Mordor Intelligence

The global cord blood banking services market is projected to grow from USD 33.85 billion in 2025 to USD 49.85 billion by 2031, with a CAGR of 6.84%. Growth is driven by increasing awareness of stem cell therapies, advancements in regenerative medicine, and expanding clinical applications in treating hematological and genetic disorders. North America leads with 39.54% market share, while Asia-Pacific emerges as a high-growth region.

GlobeNewswire Inc.

Stem Cell Banking Market to Surpass Value of USD 18.65 Billion By 2031 | SkyQuest Technology

The global stem cell banking market is projected to reach $18.65 billion by 2031, growing at a CAGR of 18.30% due to advancements in cryopreservation, cell bank preparation, and the rising adoption of stem cell therapy. The market is driven by increased awareness of stem cell therapy, growing healthcare investments, and trends in personalized medicine.

GlobeNewswire Inc.

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2022

OLDSMAR, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2022.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
May 21, 2025$0.15May 30, 2025recurring
Feb 14, 2025$0.25Feb 28, 2025recurring
Nov 15, 2024$0.25Nov 29, 2024recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.